Hydralazine Hydrochloride 50 mg Tablet, 100-count — NDC 67877-291-01 (Billing 67877-0291-01)
This is a package of 100 tablets of Hydralazine Hydrochloride 50 mg Tablet from Ascend Laboratories, LLC, marketed since Nov 2009 and currently FDA-listed. It is the main listing for this product, which comes in 3 package sizes.
Identity & classification
Regulatory identifiers FDA, NLM and CMS codes for this package
- RxCUI (RxNorm): 905199
Where does this data come from?
- FDA openFDA NDC Directory · synced Oct 1, 2026
- FDA label on DailyMed · label index refreshed Oct 1, 2026
- RxNorm (NLM RxNav) · catalog refreshed Oct 1, 2026
- Medi-Span GPI (licensed)
- First Databank (licensed) · refreshed Oct 1, 2026
RxNorm drug class
This medicine belongs to the Arteriolar Vasodilator class.
Where does this data come from?
- RxClass (NLM) · catalog refreshed Oct 1, 2026
Clinical
Hydralazine is used to treat high blood pressure. Hydralazine is in a class of medications called vasodilators. It works by relaxing the blood vessels so that blood can flow more easily through the body. High blood pressure is a common condition and when not treated, can cause damage to the brain, heart, blood vessels, kidneys and other parts of the body. Damage to these organs may cause heart disease, a heart attack, heart failure, stroke, kidney failure, loss of vision, and other problems. In addition to taking medication, making lifestyle changes will also help to control your blood pressur...
Read the full MedlinePlus article ↗- Hydralazine is a blood pressure–lowering medication. It works by relaxing the walls of your arteries so blood can flow through more easily, which brings your blood pressure down. K...
- What exactly is hydralazine supposed to do for me?
- Your prescription label and your doctor's instructions are the best guide for your specific regimen. Tablets are generally taken several times a day, and your doctor will have star...
- How do I take my hydralazine tablets — do they need to be taken with food?
Patient education
Supplement & herbal interactions
Hydralazine may be associated with lower levels of 2 nutrients — worth a chat with your pharmacist, not a cause for alarm.
Where does this data come from?
- MedlinePlus (NLM) · refreshed Oct 1, 2026
- FDA label on DailyMed · label index refreshed Oct 1, 2026
Ask a licensed pharmacist directly — free, answered by our team.
Pricing
A drug doesn't have one price. Each row is a different public payment system, and none is what you'd pay at the counter — that depends on your insurance. The ⓘ on each row explains what it measures.
| Price system | Per each | Per package |
|---|---|---|
| Retail pharmacies payNADAC · weekly | Not in the retail survey — common for institutional, discontinued, or low-volume packs. | |
| Medicaid paysCMS SDUD · 12 mo | No recent Medicaid claims on file for this NDC — rare and low-volume NDCs are suppressed in the public data. | |
| Medicare drug plans payPart D · Q2 2026 | $0.0607 | $6.07 / 100 tablets |
Where does this data come from?
- CMS NADAC weekly file
- CMS ASP pricing files · refreshed Sep 20, 2026
- CMS Medicaid State Drug Utilization Data · refreshed Oct 2, 2026
- CMS Part D plan pricing files · refreshed Sep 24, 2026
- VA National Acquisition Center price file
Packaging — all sizes for this product
| Package NDC | Description | Marketing start | Marketing end | Status |
|---|---|---|---|---|
| 67877-0291-01 You're viewing this Main listing | 100 TABLET in 1 BOTTLE | 2009-11-24 | — | Active |
| 67877-0291-05 67877-291-05 | 500 TABLET in 1 BOTTLE | 2009-11-24 | — | Active |
| 67877-0291-10 67877-291-10 | 1000 TABLET in 1 BOTTLE | 2009-11-24 | — | Active |
You're viewing the smallest of 3 pack sizes for this product.
Pack size FAQ
What quantity is in this package?
How does this package differ from NDC 67877-0291-05?
What NDC number is used to bill for this package of Hydralazine Hydrochloride 50 mg Tablet?
Therapeutic equivalents
| Product | Labeler | Pack | NADAC/unit | TE | Status | Price vs. this |
|---|---|---|---|---|---|---|
| Hydralazine Hydrochloride 50 mg 00904-7449-61 | Major | 100 tablets | $0.045 | AA | Availability likely | — |
| Hydralazine Hydrochloride 50 mg 23155-0003-01 | Heritage | 100 tablets | $0.045 | — | Discontinued | — |
| Hydralazine Hydrochloride 50 mg 23155-0834-01 | Heritage | 100 tablets | $0.045 | AA | Availability likely | — |
| Hydralazine Hydrochloride 50 mg 31722-0521-01 | Camber | 100 tablets | $0.045 | AA | Availability likely | — |
| Hydralazine Hydrochloride 50 mg 50111-0328-01 | Teva | 100 tablets | $0.045 | AA | Availability likely | — |
| Hydralazine Hydrochloride 50 mg 50228-0184-01 | ScieGen | 100 tablets | $0.045 | AA | Availability likely | — |
| Hydralazine Hydrochloride 50 mg 51079-0076-20 | Mylan | 100 tablets | $0.045 | AA | Availability likely | — |
| Hydralazine Hydrochloride 50 mg 60687-0833-01 | American | 100 tablets | $0.045 | AA | Availability likely | — |
| Hydralazine Hydrochloride 50 mg 62135-0581-12 | Chartwell | 120 tablets | $0.045 | — | Availability likely | — |
| HydrALAZINE Hydrochloride 50 mg 64380-0735-06 | Strides | 100 tablets | $0.045 | AA | Availability likely | — |
| HydrALAZINE Hydrochloride 50 mg 76282-0311-01 | Exelan | 100 tablets | $0.045 | — | Availability likely | — |
| Hydralazine Hydrochloride 50 mg 33342-0376-11 | Macleods | 100 tablets | — | — | FDA listed | — |
| Hydralazine Hydrochloride 50 mg 43063-0392-90 | PD-Rx | 90 tablets | — | — | FDA listed | — |
| Hydralazine Hydrochloride 50 mg 48433-0048-20 | Safecor | 100 tablets | — | AA | FDA listed | — |
| Hydralazine Hydrochloride 50 mg 50090-0139-00 | A-S | 100 tablets | — | AA | Discontinued | — |
| Hydralazine Hydrochloride 50 mg 50090-6608-00 | A-S | 90 tablets | — | AA | FDA listed | — |
| Hydralazine Hydrochloride 50 mg 50090-6684-00 | A-S | 90 tablets | — | AA | FDA listed | — |
| Hydralazine Hydrochloride 50 mg 50090-7210-01 | A-S | 60 tablets | — | AA | FDA listed | — |
| Hydralazine Hydrochloride 50 mg 50090-7212-00 | A-S | 90 tablets | — | AA | FDA listed | — |
| Hydralazine Hydrochloride 50 mg 51655-0916-26 | Northwind | 90 tablets | — | — | Discontinued | — |
| Hydralazine Hydrochloride 50 mg 55154-0187-00 | Cardinal | 10 tablets | — | AA | FDA listed | — |
| Hydralazine Hydrochloride 50 mg 55154-2140-00 | Cardinal | 10 tablets | — | AA | FDA listed | — |
| Hydralazine Hydrochloride 50 mg 55154-5085-00 | Cardinal | 10 tablets | — | AA | FDA listed | — |
| Hydralazine Hydrochloride 50 mg 63629-5246-01 | Bryant | 30 tablets | — | AA | FDA listed | — |
| Hydralazine Hydrochloride 50 mg 63629-8497-01 | Bryant | 1000 tablets | — | AA | FDA listed | — |
| Hydralazine Hydrochloride 50 mg 67046-1517-03 | Coupler | 30 tablets | — | AA | FDA listed | — |
| Hydralazine Hydrochloride 50 mgthis 67877-0291-01 | Ascend | 100 tablets | — | AA | FDA listed | — |
| Hydralazine Hydrochloride 50 mg 68071-1940-03 | NuCare | 30 tablets | — | AA | FDA listed | — |
| Hydralazine Hydrochloride 50 mg 68462-0343-01 | Glenmark | 100 tablets | — | AA | FDA listed | — |
| Hydralazine Hydrochloride 50 mg 70518-4007-00 | REMEDYREPACK | 30 tablets | — | AA | FDA listed | — |
| HydrALAZINE Hydrochloride 50 mg 71205-0072-30 | Proficient | 30 tablets | — | AA | FDA listed | — |
| Hydralazine Hydrochloride 50 mg 71209-0017-05 | Cadila | 100 tablets | — | AA | FDA listed | — |
| Hydralazine Hydrochloride 50 mg 71335-9756-01 | Bryant | 30 tablets | — | AA | FDA listed | — |
| Hydralazine Hydrochloride 50 mg 71610-0562-60 | Aphena | 90 tablets | — | AA | FDA listed | — |
| Hydralazine Hydrochloride 50 mg 72162-1537-00 | Bryant | 1000 tablets | — | AA | FDA listed | — |
| Hydralazine Hydrochloride 50 mg 72241-0005-05 | Modavar | 100 tablets | — | AA | FDA listed | — |
| Hydralazine 50 mg 75834-0127-00 | Nivagen | 1000 tablets | — | AA | Discontinued | — |
| Hydralazine Hydrochloride 50 mg 77771-0184-01 | Radha | 100 tablets | — | AA | FDA listed | — |
| HydrALAZINE Hydrochloride 50 mg 67046-2080-03 | Coupler | 30 tablets | — | AA | FDA listed | — |
| Hydralazine Hydrochloride 50 mg 55154-0287-00 | Cardinal | 10 tablets | — | AA | FDA listed | — |
Where does this data come from?
- FDA openFDA NDC Directory · synced Oct 1, 2026
- FDA Orange Book · refreshed Sep 3, 2026
- CMS NADAC weekly file
Availability & generic status
This product is an FDA-approved generic. Other versions of the same drug are listed under Therapeutic equivalents, least expensive first.
Where does this data come from?
- FDA Orange Book · refreshed Sep 3, 2026
What it looks like
Where does this data come from?
- FDA label on DailyMed · label index refreshed Oct 1, 2026
Inactive Ingredients / Excipients
Inactive ingredients, also called excipients, are components of the drug product other than the active ingredient. They may include fillers, dyes, coatings, preservatives, flavors, or other formulation ingredients.
💡 Tap an ingredient (hover on desktop) to see what it is and why it’s used.
-
UNII OP1R32D61U
Microcrystalline cellulose is a purified form of cellulose, a natural fiber from plant sources. It acts as a binder and filler in tablets and capsules, helping hold ingredients together and give the medicine its shape and size.
-
UNII H77VEI93A8
A synthetic yellow dye used to color medications. It helps identify the drug and make it visually distinctive, with no effect on how the medicine works.
-
UNII 3OWL53L36A
A natural sugar alcohol derived from seaweed or synthesized in the lab. It's used as a filler to add bulk, a sweetener in sugar-free formulas, and a disintegrant to help tablets break apart in the stomach.
-
UNII U725QWY32X
Povidone K30 is a synthetic polymer made from petroleum. It acts as a binder to hold tablet ingredients together and as a disintegrant to help the tablet break apart in the stomach so the medicine can be absorbed.
-
UNII ETJ7Z6XBU4
Silicon dioxide is a naturally occurring mineral used as a glidant and anti-caking agent. It helps powder ingredients flow smoothly and prevents clumping during manufacturing and storage.
-
UNII 5856J3G2A2
A starch-based powder made from potatoes and processed with sodium. It acts as a disintegrant, helping the tablet or capsule break apart quickly in the stomach so the medicine can be absorbed.
-
UNII 4ELV7Z65AP
Stearic acid is a fatty acid derived from plant or animal sources. It acts as a binder and lubricant in tablets and capsules, helping them hold together and flow smoothly during manufacturing.
7 inactive ingredients listed in the exact product block matched to this NDC.
Where does this data come from?
ingredient classCode="IACT" elements from the exact product block matched by this NDC. Label-section narrative from DailyMed / the openFDA label index is shown separately when available.- FDA label on DailyMed · label index refreshed Oct 1, 2026
- FDA openFDA NDC Directory · synced Oct 1, 2026
Inactive ingredient FAQ
Are inactive ingredients the same for every manufacturer?
Why might an inactive ingredient be missing?
Can inactive ingredients matter?
Manufacturer & labeler
Where does this data come from?
- FDA openFDA NDC Directory · synced Oct 1, 2026
- Drugs@FDA
Full prescribing information FDA SPL
🎯 Indications and Usage ▾
INDICATIONS & USAGE Essential hypertension, alone or as an adjunct.
⏱️ Dosage and Administration ▾
DOSAGE & ADMINISTRATION Initiate therapy in gradually increasing dosages; adjust according to individual response. Start with 10 mg four times daily for the first 2 to 4 days, increase to 25 mg four times daily for the balance of the first week. For the second and subsequent weeks, increase dosage to 50 mg four times daily.
For maintenance, adjust dosage to the lowest effective levels. The incidence of toxic reactions, particularly the L.E. cell syndrome, is high in the group of patients receiving large doses of HydrALAZINE . In a few resistant patients, up to 300 mg of HydrALAZINE daily may be required for a significant antihypertensive effect.
In such cases, a lower dosage of HydrALAZINE combined with a thiazide and/or reserpine or a beta blocker may be considered. However, when combining therapy, individual titration is essential to ensure the lowest possible therapeutic dose of each drug.
⛔ Contraindications ▾
CONTRAINDICATIONS Hypersensitivity to HydrALAZINE ; coronary artery disease; mitral valvular rheumatic heart disease.
⚠️ Warnings ▾
WARNINGS In a few patients HydrALAZINE may produce a clinical picture simulating systemic lupus erythematosus including glomerulonephritis. In such patients HydrALAZINE should be discontinued unless the benefit-to-risk determination requires continued antihypertensive therapy with this drug. Symptoms and signs usually regress when the drug is discontinued but residua have been detected many years later.
Long-term treatment with steroids may be necessary. ( See PRECAUTIONS , Laboratory Tests. )
🤒 Adverse Reactions ▾
ADVERSE REACTIONS Adverse reactions with HydrALAZINE are usually reversible when dosage is reduced. However, in some cases it may be necessary to discontinue the drug. The following adverse reactions have been observed, but there has not been enough systematic collection of data to support an estimate of their frequency.
Common: Headache, anorexia, nausea, vomiting, diarrhea, palpitations, tachycardia, angina pectoris. Less Frequent:Digestive: constipation, paralytic ileus. Cardiovascular: hypotension, paradoxical pressor response, edema.
Respiratory: dyspnea. Neurologic: peripheral neuritis, evidenced by paresthesia, numbness, and tingling; dizziness; tremors; muscle cramps; psychotic reactions characterized by depression, disorientation, or anxiety. Genitourinary: difficulty in urination.
Hematologic: blood dyscrasias, consisting of reduction in hemoglobin and red cell count, leukopenia, agranulocytosis, purpura; lymphadenopathy; splenomegaly. Hypersensitive Reactions: rash, urticaria, pruritus, fever, chills, arthralgia, eosinophilia, and rarely, hepatitis. Other: nasal congestion, flushing, lacrimation, conjunctivitis.
🆘 Overdosage ▾
OVERDOSAGE Acute Toxicity No deaths due to acute poisoning have been reported. Highest known dose survived: adults, 10 g orally. Oral LD 50 in rats: 173 and 187 mg/kg.
Signs and Symptoms Signs and symptoms of overdosage include hypotension, tachycardia, headache, and generalized skin flushing. Complications can include myocardial ischemia and subsequent myocardial infarction, cardiac arrhythmia, and profound shock. Treatment There is no specific antidote.
The gastric contents should be evacuated, taking adequate precautions against aspiration and for protection of the airway. An activated charcoal slurry may be instilled if conditions permit. These manipulations may have to be omitted or carried out after cardiovascular status has been stabilized, since they might precipitate cardiac arrhythmias or increase the depth of shock.
Support of the cardiovascular system is of primary importance. Shock should be treated with plasma expanders. If possible, vasopressors should not be given, but if a vasopressor is required, care should be taken not to precipitate or aggravate cardiac arrhythmia.
Tachycardia responds to beta blockers. Digitalization may be necessary, and renal function should be monitored and supported as required. No experience has been reported with extracorporeal or peritoneal dialysis.
🧬 Clinical Pharmacology ▾
CLINICAL PHARMACOLOGY Although the precise mechanism of action of HydrALAZINE is not fully understood, the major effects are on the cardiovascular system. HydrALAZINE apparently lowers blood pressure by exerting a peripheral vasodilating effect through a direct relaxation of vascular smooth muscle. HydrALAZINE , by altering cellular calcium metabolism, interferes with the calcium movements within the vascular smooth muscle that are responsible for initiating or maintaining the contractile state.
The peripheral vasodilating effect of HydrALAZINE results in decreased arterial blood pressure (diastolic more than systolic); decreased peripheral vascular resistance; and an increased heart rate, stroke volume, and cardiac output. The preferential dilatation of arterioles, as compared to veins, minimizes postural hypotension and promotes the increase in cardiac output. HydrALAZINE usually increases renin activity in plasma, presumably as a result of increased secretion of renin by the renal juxtaglomerular cells in response to reflex sympathetic discharge.
This increase in renin activity leads to the production of angiotensin II, which then causes stimulation of aldosterone and consequent sodium reabsorption. Hydralazine also maintains or increases renal and cerebral blood flow. HydrALAZINE is rapidly absorbed after oral administration, and peak plasma levels are reached at 1 to 2 hours.
Plasma levels of apparent HydrALAZINE decline with a half-life of 3 to 7 hours. Binding to human plasma protein is 87%. Plasma levels of HydrALAZINE vary widely among individuals.
HydrALAZINE is subject to polymorphic acetylation; slow acetylators generally have higher plasma levels of HydrALAZINE and require lower doses to maintain control of blood pressure. HydrALAZINE undergoes extensive hepatic metabolism; it is excreted mainly in the form of metabolites in the urine.
📦 How Supplied / Storage and Handling ▾
HOW SUPPLIED HydrALAZINE Hydrochloride Tablets, USP: 10 mg Orange colored, slightly mosaic, circular, biconvex uncoated tablets debossed with ‘293’ on one side and plain on other side Bottles of 100 Tablets NDC 67877-293-01 Bottles of 500 Tablets NDC 67877-293-05 Bottles of 1000 Tablets NDC 67877-293-10 25 mg Orange colored, slightly mosaic, circular, biconvex uncoated tablets debossed with ‘292’ on one side and plain on other side Bottles of 100 Tablets NDC 67877-292-01 Bottles of 500 Tablets NDC 67877-292-05 Bottles of 1000 Tablets NDC 67877-292-10 50 mg Orange colored, slightly mosaic, circular, biconvex uncoated tablets debossed with ‘291’ on one side and plain on other side Bottles of 100 Tablets NDC 67877-291-01 Bottles of 500 Tablets NDC 67877-291-05 Bottles of 1000 Tablets NDC 67877-291-10 100 mg Orange colored, slightly mosaic, circular, biconvex uncoated tablets debossed with ‘290’ on one side and plain on other side Bottles of 100 Tablets NDC 67877-290-01 Bottles of 500 Tablets NDC 67877-290-05 Dispense in a tight, light-resistant container.
Store at 20° to 25°C (68° to 77°F) [See USP Controlled Room Temperature]. KEEP THIS AND ALL MEDICATIONS OUT OF THE REACH OF CHILDREN. Manufactured by: ALKEM LABORATORIES LIMITED H.O.: ALKEM HOUSE, Senapati Bapat Marg, Lower Parel, Mumbai - 400 013, INDIA Distributed by: Ascend Laboratories Parsippany, NJ 07054 Revised: December,2017 PT 1368-02
📋 Description ▾
DESCRIPTION HydrALAZINE hydrochloride, USP, is an antihypertensive, for oral administration. Its chemical name is 1-hydrazinophthalazine monohydrochloride, and its structural formula is: C 8 H 8 N 4 • HCl HydrALAZINE hydrochloride, USP is a white to off-white, odorless crystalline powder. It is soluble in water, slightly soluble in alcohol, and very slightly soluble in ether.
It melts at about 275°C, with decomposition, and has a molecular weight of 196.64. Each tablet for oral administration contains 10 mg, 25 mg, 50 mg or 100 mg HydrALAZINE hydrochloride, USP. Tablets also contain microcrystalline cellulose, sodium starch glycolate, stearic acid, povidone K-30, colloidal silicon dioxide, mannitol and FD&C Yellow No 6. structure
⚠️ Precautions ▾
PRECAUTIONS General Myocardial stimulation produced by HydrALAZINE can cause anginal attacks and ECG changes of myocardial ischemia. The drug has been implicated in the production of myocardial infarction. It must, therefore, be used with caution in patients with suspected coronary artery disease.
The “hyperdynamic” circulation caused by HydrALAZINE may accentuate specific cardiovascular inadequacies. For example, HydrALAZINE may increase pulmonary artery pressure in patients with mitral valvular disease. The drug may reduce the pressor responses to epinephrine.
Postural hypotension may result from HydrALAZINE but is less common than with ganglionic blocking agents. It should be used with caution in patients with cerebral vascular accidents. In hypertensive patients with normal kidneys who are treated with HydrALAZINE , there is evidence of increased renal blood flow and a maintenance of glomerular filtration rate.
In some instances where control values were below normal, improved renal function has been noted after administration of HydrALAZINE . However, as with any antihypertensive agent, HydrALAZINE should be used with caution in patients with advanced renal damage. Peripheral neuritis, evidenced by paresthesia, numbness, and tingling, has been observed.
Published evidence suggests an antipyridoxine effect, and that pyridoxine should be added to the regimen if symptoms develop. Information for Patients Patients should be informed of possible side effects and advised to take the medication regularly and continuously as directed. Laboratory Tests Complete blood counts and antinuclear antibody titer determinations are indicated before and periodically during prolonged therapy with HydrALAZINE even though the patient is asymptomatic.
These studies are also indicated if the patient develops arthralgia, fever, chest pain, continued malaise, or other unexplained signs or symptoms. A positive antinuclear antibody titer requires that the physician carefully weigh the implications of the test results against the benefits to be derived from antihypertensive therapy with HydrALAZINE . Blood dyscrasias, consisting of reduction in hemoglobin and red cell count, leukopenia, agranulocytosis, and purpura, have been reported.
If such abnormalities develop, therapy should be discontinued. Drug/Drug Interactions MAO inhibitors should be used with caution in patients receiving HydrALAZINE . When other potent parenteral antihypertensive drugs, such as diazoxide, are used in combination with HydrALAZINE , patients should be continuously observed for several hours for any excessive fall in blood pressure.
Profound hypotensive episodes may occur when diazoxide injection and HydrALAZINE are used concomitantly. Drug/Food Interactions Administration of HydrALAZINE with food results in higher plasma levels. Carcinogenesis, Mutagenesis, Impairment of Fertility In a lifetime study in Swiss albino mice, there was a statistically significant increase in the incidence of lung tumors (adenomas and adenocarcinomas) of both male and female mice given HydrALAZINE continuously in their drinking water at a dosage of about 250 mg/kg per day (about 80 times the maximum recommended human dose).
In a 2-year carcinogenicity study of rats given HydrALAZINE by gavage at dose levels of 15, 30, and 60 mg/kg/day (approximately 5 to 20 times the recommended human daily dosage), microscopic examination of the liver revealed a small, but statistically significant, increase in benign neoplastic nodules in male and female rats from the high-dose group and in female rats from the intermediate-dose group. Benign interstitial cell tumors of the testes were also significantly increased in male rats from the high-dose group.
The tumors observed are common in aged rats and a significantly increased incidence was not observed until 18 months of treatment. HydrALAZINE was shown to be mutagenic in bacterial systems (Gene Mutation and DNA Repair) and in one of two rats and one rabbit he… [Excerpted — this section continues on DailyMed.]
📄 Package Label / Principal Display Panel ▾
PACKAGE LABEL.PRINCIPAL DISPLAY PANEL HydrALAZINE Hydrochloride Tablets, USP 10 mg - Container Label NDC 67877-293-01 HydrALAZINE Hydrochloride Tablets, USP 10 mg Rx Only 100 Tablets HydrALAZINE Hydrochloride Tablets, USP 25 mg - Container Label NDC 67877-292-05 HydrALAZINE Hydrochloride Tablets, USP 25 mg Rx Only 500 Tablets HydrALAZINE Hydrochloride Tablets, USP 50 mg - Container Label NDC 67877-291-10 HydrALAZINE Hydrochloride Tablets, USP 50 mg Rx Only 1000 Tablets HydrALAZINE Hydrochloride Tablets, USP 100 mg - Container Label NDC 67877-290-01 HydrALAZINE Hydrochloride Tablets, USP 100 mg Rx Only 100 Tablets 100s-10mg 500s-25mg 1000s-50mg 100s-100mg
About this NDC listing & data coverage
What data is (and isn’t) available for this NDC — tap to expand
| NDC identity (package / product / labeler codes) | ✓ Available |
| Labeler | ✓ Available |
| Product & package description | ✓ Available |
| Marketing category & status | ✓ Available |
| Active ingredient / dosage form / route | ✓ Available |
| FDA label (SPL via DailyMed) | ✓ Available |
| Package photos | ✓ Available |
| Inactive ingredients (structured) | ✓ Available |
| NADAC pharmacy acquisition price (CMS) | — Not published for this NDC CMS publishes NADAC only for NDCs reported in its retail-pharmacy survey. |
| Orange Book / therapeutic-equivalence data | ✓ Available |
| HCPCS J-code billing crosswalk | — Not published for this NDC Most self-administered / retail products have no J-code — that is normal. |
| Medicaid utilization (CMS SDUD) | — Not published for this NDC CMS reports utilization only for NDCs with Medicaid claims above its privacy threshold. |